AivoCode is developing molecular zip code-based therapeutics to target specific diseased regions in the brain, aiming to enhance treatment outcomes for traumatic brain injury and neurodegenerative disorders like Alzheimer’s disease. By focusing on early intervention and precise targeting, AivoCode seeks to improve patient recovery and management of these conditions.
Funding
$600K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for traumatic brain injury (TBI) and neurodegenerative diseases like Alzheimer's often involve invasive procedures or systemic drug delivery, leading to imprecise targeting, off-target effects, and limited efficacy. Treating neurodegenerative diseases late in their progression also reduces the likelihood of successful intervention.
Solution
AivoCode is developing molecular zip code-based therapeutics designed to selectively target diseased regions or cell types within the brain. This approach aims to improve treatment outcomes for neurological disorders by delivering therapeutic agents directly to the affected areas, minimizing off-target effects and maximizing therapeutic impact. For TBI, AivoCode's therapeutic aims to reduce secondary injury. For Alzheimer's disease, AivoCode is developing therapeutic antibodies targeting an unexplored target present early in the disease within brain blood vessels, enabling early intervention.
Target Audience
The primary target audience includes patients suffering from traumatic brain injury and neurodegenerative diseases, as well as clinicians and researchers focused on developing and improving treatments for these conditions.
Features
- Molecular zip code technology for precise targeting of therapeutics to specific brain regions.
- Development of a proprietary therapeutic to reduce secondary injury following TBI.
- Therapeutic antibodies targeting a novel, early-stage target in Alzheimer's disease blood vessels.
- Focus on early therapeutic intervention for neurodegenerative diseases.